Onyx Pharmaceuticals

Overview

Compare with another stock.

• TickerONXX on NASDAQ¹
• Industrybiotechnology¹
• HeadquartersSouth San Francisco¹
• Websitewww.onyx.com
• Incorporated inDE⁴
• Business address249 E. Grand Ave., South San Francisco, Ca 94080⁴
• Filer categoryLarge Accelerated⁴

See how the biggest companies compare on our leaderboards

Onyx Pharmaceuticals, Inc. was a pharmaceutical company headquartered in South San Francisco, California that developed and marketed cancer treatment medications. It was founded and incorporated with the California Secretary of State in February 1992 by venture capitalist Kevin J. Kinsella and Frank McCormick, Ph.D., FRS, D.Sc. (Hon.), a renowned British-American biochemist. McCormick served as the chief scientific officer until 1996, while Kinsella chaired the company's board of directors. On March 26, 1996, Onyx withdrew its corporate registration with the California Secretary of State and reincorporated in the state of Delaware in advance of successfully taking the company public on the NASDAQ exchange using National Market symbol ONXX on May 9, 1996. In 2009, the company acquired private biotechnology company Proteolix for US$276 million in cash plus additional milestone payments. In January 2012, the company was named "the top biotechnology takeover target in 2012" in an industry survey conducted by the ISI Group. Onyx president and CEO N. Anthony Coles had said that Onyx liked its prospects as an independent company and was focused on bringing new therapies to patients. However, by the end of August 2013, Amgen announced that it was acquiring Onyx in an agreed US$10.4 billion deal.³

Leadership

Who has led Onyx Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

• FounderFrank McCormick¹

Timeline

1. Aug 25, 2013Dissolved Dissolved¹
2. May 9, 1996Went public Listed on NASDAQ¹
3. Feb 1992Founded Founded¹

Links

• WikipediaOnyx Pharmaceuticals
• WikidataQ7095196
• SEC EDGARCIK 1012140